DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for ileocolitis — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIleocolitis maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ileocolitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 10 (IL10) — IL10 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2ILK · 1.6 Å · ligand none (apo structure). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1957 · 22 citations
ILEOCOLITIS
Abstract• Regional iletis may be associated with ulcerative or granulomatous colitis, the diagnosis depending upon the amount of fibrosis and scarring as well as the presence of giant cell systems and epithelioid cells. Ileocolitis is a term used to indicate the presence of the combined forms, whose presenting symptoms are fever, cramps, and diarrhea. Medical treatment should be attempted in all cases, unless there are definite indications for surgical therapy such as recurrent massive hemorrhage, recurrent bouts of intestinal obstruction, or persistent fistulas.
AbstractTo the Editor:— Occasionally, patients with ulcerative colitis, regional enteritis, or ileocolitis are observed who give a family history of inflammatory bowel disease. During the past year, we have studied six individuals, representing four families with inflammatory bowel disease. Method: Chromosome studies were done by use of venous blood, according to the method of Moorhead et al, (Exp Cell Res20:613, 1960) with modifications. The chromosome number in all patients studied was 46, and the idiograms were normal. The accompanying Table describes the patients. Comment: In a recent review dealing with familial ulcerative colitis, ileitis, and ileocolitis, Kirsner and Spencer (Ann Intern Med59:133-144, 1963) reported that 91 of 1,339 patients gave evidence of similar disease in relatives. It was rare for this disease to occur in more than two members of one family. Morris (Gut6:176, 1965) recently described a family in which eight members had
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
